Sumitra Ananda

Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.

Nikki L Burdett, Madelynne O Willis, Kathryn Alsop, Allison L Hunt, Ahwan Pandey, Phineas T Hamilton, Tamara Abulez, Xuan Liu, Therese Hoang, Stuart Craig, Sian Fereday, Joy Hendley, Dale W Garsed, Katy Milne, Shreena Kalaria, Ashley Marshall, Brian L Hood, Katlin N Wilson, Kelly A Conrads, Kathleen I Pishas, et al.

Journal article  |  2023  |  Nat Genet

High-grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency and, wh..

Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.

Jordan Santucci, Mark Tacey, Benjamin Thomson, Michael Michael, Rachel Wong, Julia Shapiro, Ross Jennens, Kate Clarke, Sharon Pattison, Matthew Burge, Rob Zielinski, Mehrdad Nikfarjam, Sumitra Ananda, Lara Lipton, Peter Gibbs, Belinda Lee

Journal article  |  2022  |  Eur J Cancer

BACKGROUND: First-line palliative chemotherapy regimens in advanced pancreatic ductal adenocarcinoma (PDAC) have not been compared..

Compliance with Therapeutic Goods Association prescribing information: weekly or second weekly cetuximab for the treatment of metastatic colorectal cancer

Matthew Loft, Jeremy Shapiro, Margaret Lee, Rachel Wong, Jeanne Tie, Suzanne Kosmider, Vanessa Wong, Azim Jalali, Belinda Lee, Sumitra S Ananda, Peter Gibbs

Journal article  |  2022  |  INTERNAL MEDICINE JOURNAL

BACKGROUND: Treatment with cetuximab provides a survival benefit for patients with RAS wild-type metastatic colorectal cancer (mCR..

Massive hypertriglyceridemia associated with paclitaxel; a case report.

Anojian Koneshamoorthy, Danielle Hulse, Chia Yuen Chong, Balasubramanian Krishnamurthy, Sumitra Ananda, Peter S Hamblin

Journal article  |  2022  |  Gynecol Oncol Rep

This report describes a patient who developed massive hypertriglyceridemia (12,488 mg/dL or 141 mmol/L) during paclitaxel and carb..

Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population

Imogen Walpole, Belinda Lee, Jeremy Shapiro, Benjamin Thomson, Lara Lipton, Sumitra Ananda, Val Usatoff, Sue-Ann Mclachlan, Brett Knowles, Adrian Fox, Rachel Wong, Prasad Cooray, Matthew Burge, Kate Clarke, Sharon Pattison, Mehrdad Nikfarjam, Niall Tebbutt, Marion Harris, Adnan Nagrial, Rob Zielinski, et al.

Conference Proceedings  |  2022  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Background: Use of neoadjuvant (NA) chemotherapy is recommended when pancreatic ductal adenocarcinoma (PDAC) is borderline resecta..

Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.

Imogen Walpole, Belinda Lee, Jeremy Shapiro, Benjamin Thomson, Lara Lipton, Sumitra Ananda, Val Usatoff, Sue-Ann Mclachlan, Brett Knowles, Adrian Fox, Rachel Wong, Prasad Cooray, Matthew Burge, Kate Clarke, Sharon Pattison, Mehrdad Nikfarjam, Niall Tebbutt, Marion Harris, Adnan Nagrial, Rob Zielinski, et al.

Journal article  |  2022  |  Asia Pac J Clin Oncol

BACKGROUND: Use of neoadjuvant (NA) chemotherapy is recommended when pancreatic ductal adenocarcinoma (PDAC) is borderline resecta..

IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.

George Au-Yeung, Mathias Bressel, Owen Prall, Daniela Surace, John Andrews, Sally Mongta, Yeh Chen Lee, Bo Gao, Tarek Meniawy, Sally E Baron-Hay, Allison Jane Black, Ganessan Kichenadasse, Sumitra Ananda, Peter Fox, David Bowtell, Linda R Mileshkin

Conference Proceedings  |  2022  |  Journal of Clinical Oncology

5515 Background: Cyclin E1 gene amplification and protein over-expression is a marker of platinum resistance in high grade serous..

Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer

A Jalali, G Gard, S Banks, C Dunn, HL Wong, R Wong, M Lee, L Gately, M Loft, JD Shapiro, S Kosmider, J Tie, S Ananda, JM Yeung, R Jennens, B Lee, J McKendrick, L Lim, A Khattak, P Gibbs

Journal article  |  2022  |  CURRENT PROBLEMS IN CANCER

For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, imp..

Early-onset pancreatic cancer: Defining contemporary presentation, treatment, and outcomes in the under 50 age group using real-world data

Shehara Ramyalini Mendis, Lara Rachel Lipton, Sumitra Ananda, Michael Michael, Sue-Anne McLachlan, Benjamin N Thomson, Brett Knowles, Adrian Fox, Mehrdad Nikfarjam, Val Usatoff, Julia Shapiro, Kate Clarke, Sharon Tracy Pattison, Cheng Ean Chee, Rob Zielinski, Rachel Wong, Peter Gibbs, Belinda Lee

Conference Proceedings  |  2022  |  JOURNAL OF CLINICAL ONCOLOGY

533 Background: The incidence of pancreatic cancer is increasing in younger patients (pts). Early onset pancreatic cancer (EOPC) ..

Options beyond BRAF targeted therapy in second-line treatment of patients with BRAFV600E mutant (BRAFmt) metastatic colorectal cancer (mCRC).

Vanessa Wong, Wei Hong, Sumitra Ananda, Catherine Dunn, Rachel Wong, Yat Hang To, Matthew E Burge, Louise M Nott, Jeanne Tie, Jeremy David Shapiro, Ross Jennens, Muhammad Adnan Khattak, Aflah Roohullah, Peter Gibbs

Conference Proceedings  |  2022  |  Journal of Clinical Oncology

47 Background: BRAFmt is a negative prognostic factor in mCRC but also identifies a patient population that may benefit from BRAF..